
Phio Pharmaceuticals Corp. (NASDAQ:PHIO – Free Report) – Investment analysts at HC Wainwright upped their FY2026 earnings per share (EPS) estimates for shares of Phio Pharmaceuticals in a note issued to investors on Monday, November 16th. HC Wainwright analyst M. Keller now expects that the company will earn ($1.41) per share for the year, up from their prior estimate of ($1.47). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Phio Pharmaceuticals’ current full-year earnings is ($1.41) per share. HC Wainwright also issued estimates for Phio Pharmaceuticals’ Q4 2026 earnings at ($0.35) EPS and FY2027 earnings at ($0.73) EPS.
Phio Pharmaceuticals (NASDAQ:PHIO – Get Free Report) last posted its earnings results on Thursday, November 5th. The company reported ($0.36) earnings per share for the quarter, hitting the consensus estimate of ($0.36).
Read Our Latest Research Report on Phio Pharmaceuticals
Phio Pharmaceuticals Trading Down 0.7%
Shares of PHIO stock opened at $0.71 on Wednesday. Phio Pharmaceuticals has a 12 month low of $0.70 and a 12 month high of $1.88. The business’s 50 day moving average is $0.92 and its two-hundred day moving average is $1.07.
About Phio Pharmaceuticals
Phio Pharmaceuticals is a clinical-stage biotechnology company developing treatments based on its INTASYL platform, a technology for delivering RNA interference compounds into cells to reduce the activity of selected genes. The company focuses on potential therapies for cancer, particularly approaches intended to strengthen the body’s immune response to tumors. Its pipeline includes candidates designed to target genes involved in immune regulation and tumor biology. These investigational treatments are being developed for solid tumors; they are not approved for commercial use.
Recommended Stories
- Five stocks we like better than Phio Pharmaceuticals
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Phio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
